Ligand Pharma (LGND) Tops Q4 EPS by 53c ; Offers Guidance
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $288.83 +1.13%
EPS Growth %: -24.9%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -24.9%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $2.02, $0.53 better than the analyst estimate of $1.49. Revenue for the quarter came in at $59.66 million versus the consensus estimate of $55.59 million.
GUIDANCE:
Ligand Pharma sees FY2026 EPS of $8.00-$9.00, versus the consensus of $8.42. Ligand Pharma sees FY2026 revenue of $245-285 million, versus the consensus of $265.7 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- U.S. moves to ban some imports of Canadian dairy, autos
- Google and Blackstone data-center venture hits delays at key sites - Bloomberg
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
